Multiparameteric Response Assessment of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Predicts Patient Survival Times

Susanne Bonekamp¹, Zhen Li², Vivek Gowdra Halappa¹, Celia Pamela Corona-Villalobos¹, Jean-Francois H. Geschwind¹, Ihab R. Kamel¹

Patient survival is the gold standard for the assessment of treatment response. The purpose of this study was to evaluate if early multiparametric assessment of treatment response is associate with patient survival in patients with hepatocellular carcinoma (HCC). To this end, HCC index lesions were analyzed using proprietary software and response was assessed based on change in tumor size as well as changes in volumetric ADC, hepatic arterial enhancement and portal venous enhancement. The combination of early change in portal venous enhancement and ADC more consistently predicted survival times than a single measurement or change in tumor size.